COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions
In COMMANDS, luspatercept, a drug that frees late-stage red cell production from TGF-beta-family braking, freed 59% of transfusion-dependent MDS patients from transfusions for at least 12 weeks, against 31% with the standard erythropoietin injection.
COMMANDS randomised patients with very-low to intermediate-risk MDS who were red-cell transfusion dependent and had not received erythropoiesis-stimulating agents to subcutaneous luspatercept every three weeks or weekly epoetin alfa. The primary endpoint was red-cell transfusion independence for at least 12 weeks with a concurrent haemoglobin rise of at least 1.5 g/dL within the first 24 weeks. In the interim analysis of 301 patients this was achieved by 58.5% versus 31.2%, with benefit in both ring-sideroblast-positive and negative disease, although the difference was smaller in patients without ring sideroblasts. Adverse events were similar, with fatigue, diarrhoea and hypertension more common with luspatercept.
- Interim analysis of 301 ESA-naive, transfusion-dependent, lower-risk MDS patients; luspatercept vs epoetin alfa.
- Primary endpoint (12-week transfusion independence plus haemoglobin rise of at least 1.5 g/dL in weeks 1-24): 58.5% vs 31.2%.
- Benefit in ring-sideroblast-positive disease was largest; the effect in ring-sideroblast-negative disease was smaller and less certain.
- Median duration of transfusion independence was longer with luspatercept.
- Safety comparable; no increase in progression to AML.
COMMANDS moved luspatercept from second line (after ESA failure, MEDALIST trial) to first line, offering transfusion-dependent lower-risk MDS patients a better chance of transfusion freedom from the start. It changed guidelines and labels in 2023. Erythropoietin remains a reasonable and cheaper option for patients without ring sideroblasts or with low transfusion burden.
- Interim analysis of an open-label trial; the composite primary endpoint is a surrogate for quality of life and survival.
- Uncertain benefit in ring-sideroblast-negative and SF3B1-unmutated disease.
- Excluded patients with del(5q) and those with high transfusion burden plus low erythropoietin only partially represented.
- Cost is far higher than epoetin.
Pages like this
not linked directly; found by shared links- TermAnaemia
Shares Imetelstat, Luspatercept, Myelodysplastic syndromes / neoplasms (MDS).
- TechnologyTransfusion support and anaemia management
Shares Imetelstat, Luspatercept, Myelodysplastic syndromes / neoplasms (MDS).
- IdeaPayers price drugs on quality-adjusted benefit, so toxicity costs the manufacturer
Shares Prices and value, Toxicity and quality of life are undervalued.
- IdeaScreen every cancer patient for financial toxicity as a vital sign, with navigation
Shares Prices and value, Toxicity and quality of life are undervalued.
- Key paperSunRISe-1: TAR-200, a gemcitabine-releasing device placed in the bladder, for BCG-unresponsive non-muscle-invasive bladder cancer
Shares Objective response rate (ORR), Toxicity and quality of life are undervalued.
- IdeaRandomised trials of stopping immunotherapy after one year versus continuing
Shares Prices and value, Toxicity and quality of life are undervalued.
- CancerMyeloproliferative neoplasms (PV, ET, myelofibrosis)
Shares Imetelstat, Luspatercept, Bristol Myers Squibb.
- IdeaExtended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable
Shares Prices and value, Toxicity and quality of life are undervalued.